LU91287I2 - Vaccin zona (vivant) et ses dérivés pharmaceutiquement acceptables (ZOSTAVAXr) - Google Patents

Vaccin zona (vivant) et ses dérivés pharmaceutiquement acceptables (ZOSTAVAXr)

Info

Publication number
LU91287I2
LU91287I2 LU91287C LU91287C LU91287I2 LU 91287 I2 LU91287 I2 LU 91287I2 LU 91287 C LU91287 C LU 91287C LU 91287 C LU91287 C LU 91287C LU 91287 I2 LU91287 I2 LU 91287I2
Authority
LU
Luxembourg
Prior art keywords
zostavaxr
live
pharmaceutically acceptable
acceptable derivatives
zoster vaccine
Prior art date
Application number
LU91287C
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25435290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91287(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of LU91287I2 publication Critical patent/LU91287I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Exchange Systems With Centralized Control (AREA)
LU91287C 1992-07-17 2006-11-15 Vaccin zona (vivant) et ses dérivés pharmaceutiquement acceptables (ZOSTAVAXr) LU91287I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91514192A 1992-07-17 1992-07-17
PCT/US1993/006581 WO1994002596A1 (fr) 1992-07-17 1993-07-13 Methode de prevention d'herpes-zoster ou de soulagement de nevralgie post-herpetique associee a la varicelle

Publications (1)

Publication Number Publication Date
LU91287I2 true LU91287I2 (fr) 2007-01-15

Family

ID=25435290

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91287C LU91287I2 (fr) 1992-07-17 2006-11-15 Vaccin zona (vivant) et ses dérivés pharmaceutiquement acceptables (ZOSTAVAXr)

Country Status (15)

Country Link
US (2) US5997880A (fr)
EP (1) EP0651789B2 (fr)
JP (3) JP4562812B2 (fr)
AT (1) ATE210722T1 (fr)
AU (1) AU687355B2 (fr)
CA (1) CA2139515C (fr)
CY (1) CY2286B1 (fr)
DE (2) DE69331322T3 (fr)
DK (1) DK0651789T4 (fr)
ES (1) ES2165367T5 (fr)
LU (1) LU91287I2 (fr)
LV (1) LV12832B (fr)
NL (1) NL300246I2 (fr)
PT (1) PT651789E (fr)
WO (1) WO1994002596A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
BRPI0906527A2 (pt) * 2008-04-04 2016-09-06 3Mm Innovative Properties Company aparelho para aplicação de bandagens em ferimentos e bandagem médica
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
WO2014043189A1 (fr) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Virus de l'herpès déficients pour la réplication conditionnelle et leur utilisation dans des vaccins
WO2015034807A2 (fr) 2013-09-05 2015-03-12 Merck Sharp & Dohme Corp. Procédés d'immunisation par l'antigène du virus varicelle-zona
CN108778289B (zh) 2015-11-06 2020-11-17 佐剂技术公司 三萜皂苷类似物
CA3061205A1 (fr) 2017-04-25 2018-11-01 Memorial Sloan Kettering Cancer Center Analogues de saponine triterpenique
BR112022017852A2 (pt) 2020-03-09 2022-11-01 Dynavax Tech Corp Vacinas para herpes zoster compreendendo um agonista de tlr9
JP7442386B2 (ja) 2020-05-14 2024-03-04 東京エレクトロン株式会社 基板処理装置

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US376788A (en) * 1888-01-24 strait
US441737A (en) * 1890-12-02 Tapping-machine for stay-bolt holes
JPS5341202B2 (fr) * 1974-03-12 1978-11-01
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
US4008317A (en) * 1975-12-29 1977-02-15 Recherche Et Industrie Therapeutiques (R.I.T.) Varicella-zoster virus vaccine and preparation thereof
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
EP0101200A3 (fr) * 1982-07-20 1985-03-06 BIO-COM Inc. Facteur de transfert pour utilisation dans le traitement d'infections virales
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
EP0211756A1 (fr) * 1985-08-01 1987-02-25 Merck & Co. Inc. Essai pour anticorps de virus Varicella-Zoster (VZV)
US4686101A (en) * 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4952674A (en) * 1986-05-02 1990-08-28 Merck & Co., Inc. Vaccine against varicella-zoster virus
NZ220645A (en) * 1986-06-20 1989-10-27 Merck & Co Inc Modified varicella-zoster virus and its cultivation
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
DE69017769T2 (de) * 1989-06-27 1995-07-13 Smithkline Beecham Biologicals S.A., Rixensart Verbindungen.
ES2150906T3 (es) * 1990-10-04 2000-12-16 Res Corp Technologies Inc Antigeno del virus varicella-zoster.

Also Published As

Publication number Publication date
NL300246I2 (nl) 2007-02-01
DE122006000063I1 (de) 2007-05-10
LV12832B (lv) 2002-09-20
JP2010189420A (ja) 2010-09-02
EP0651789A4 (fr) 1996-06-26
DE69331322T3 (de) 2009-10-22
ES2165367T3 (es) 2002-03-16
AU687355B2 (en) 1998-02-26
CA2139515C (fr) 2008-12-23
WO1994002596A1 (fr) 1994-02-03
US6214354B1 (en) 2001-04-10
LV12832A (en) 2002-05-20
CA2139515A1 (fr) 1994-02-03
CY2286B1 (en) 2003-07-04
ATE210722T1 (de) 2001-12-15
JPH07509244A (ja) 1995-10-12
EP0651789B1 (fr) 2001-12-12
DK0651789T4 (da) 2009-07-27
JP4562812B2 (ja) 2010-10-13
PT651789E (pt) 2002-05-31
DK0651789T3 (da) 2002-03-11
JP2004323531A (ja) 2004-11-18
AU4676093A (en) 1994-02-14
DE69331322T2 (de) 2002-08-08
DE69331322D1 (de) 2002-01-24
US5997880A (en) 1999-12-07
EP0651789A1 (fr) 1995-05-10
EP0651789B2 (fr) 2009-05-20
NL300246I1 (nl) 2007-01-02
ES2165367T5 (es) 2009-08-05

Similar Documents

Publication Publication Date Title
LU93100I2 (fr) Talimogene laherparepvec et ses dérivés pharmaceutiquement acceptables (imlygic)
LU91287I2 (fr) Vaccin zona (vivant) et ses dérivés pharmaceutiquement acceptables (ZOSTAVAXr)
CO4960659A1 (es) Vacuna que comprende un antigeno de virus de la hepatitis b y un antigeno del virus herpes simplex
ES2059612T3 (es) Vacuna con coadyuvante, combinada para la hepatitis a, b.
BR1100846A (pt) Composto, e, composição antiviral útil e processo para tratar o vìrus do herpes simples 1 e 2, vìrus varicella zoster e citomegalovìrus humano
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
ES2118963T3 (es) Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
DK0506778T3 (da) Substituerede 4-phenyl-4-piperidincarboxamider med både lokal anæstetisk og analgetisk virkning samt fremgangsmåder til deres fremstilling
DE69735634D1 (de) Substituierte cyclopentanderivate die als neuramidase-inhibitoren nuetzlich sind
ES2035818T3 (es) Mutantes de delecion de la timidin-kinasa del virus del herpes bovino-1, vacunas contra la rinotraqueitis bovina infecciosa que los contienen y metodos para su produccion y uso.
UA40571C2 (uk) Мутант коров'ячого вірусу герпесу типу 1 (bhv-1), композиція вакцини для вакцинації тварин для захисту їх від bhv-1, композиція вакцини для вакцинації тварин для захисту їх від патогена
DK0541692T3 (da) Herpes simplex virus VP-16-vacciner
ATE200735T1 (de) Impfstoffkonjugat
AU551678B2 (en) Antiviral alpha alpha dialkyl adamantylethylamines
DK0841943T3 (da) Avirulente herpesvira anvendelige som tumordræbende midler og vacciner
AU5994596A (en) Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising fro m exposure to an antigen
ES2068883T3 (es) Vacunas combinadas vivas.
ES2150906T3 (es) Antigeno del virus varicella-zoster.
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse
EP0293333A3 (en) A synthetic nonapeptide of use as an adjuvant
ES2185576T3 (es) Mezcla de sustantcias de accion terapeutica que contiene s-acetilglutation y aciclovir.
NO963554L (no) Diestere av kullsyre utstyrt med antiviral og antiinflammatorisk virkning
DING et al. The study of pathogenic bacteria and whole cell vaccine on Sparus latus vibrio disease
USD205506S (en) Side chair
IT1254147B (it) Metodo di rivelazione di marcatori tumorali.